• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of oenvmedOccupational and Environmental MedicineVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Occup Environ Med. Apr 2001; 58(4): 261–266.
PMCID: PMC1740123

Erionite bodies and fibres in bronchoalveolar lavage fluid (BALF) of residents from Tuzköy, Cappadocia, Turkey


OBJECTIVES—The high incidence of malignant mesothelioma in some villages of Cappadocia (Turkey) is due to environmental exposure to erionite fibres. The aim was to evaluate the fibre burden in bronchoalveolar lavage fluid (BALF) from inhabitants of an erionite village and compare it with Turkish subjects with or without environmental exposure to tremolite asbestos.
METHODS—Ferruginous bodies (FBs) and fibres were measured and analyzed by light and transmission electron microscopy (TEM) in the BALF of 16 subjects originating from Tuzköy.
RESULTS—FBs were detected in the BALF of 12 subjects, with concentrations above 1 FB/ml in seven of them. Erionite was the central fibre of 95.7% of FBs. Erionite fibres were found in the BALF of all subjects, by TEM, and these fibres were low in Mg, K, and Ca compared with erionite from Tuzköy soil. The mean concentration of erionite fibres in BALF was similar to that of tremolite fibres in Turks with environmental exposure to tremolite. The proportion of fibres longer than 8 µm in BALF represented 35.6% for erionite compared with 14.0% for tremolite. The asbestos fibre concentrations in erionite villagers was not different from that in Turks without environmental exposure to tremolite.
CONCLUSION—Analysis of BALF gives information about fibre retention in populations environmentally exposed to erionite for whom data on fibre burden from lung tissue samples are scarce. This may apply to exposed Turks having emigrated to other countries.

Keywords: ferruginous body; asbestos body; environmental exposure; mesothelioma

Full Text

The Full Text of this article is available as a PDF (215K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Baris I, Simonato L, Artvinli M, Pooley F, Saracci R, Skidmore J, Wagner C. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int J Cancer. 1987 Jan 15;39(1):10–17. [PubMed]
  • Maltoni C, Minardi F, Morisi L. Pleural mesotheliomas in Sprague-Dawley rats by erionite: first experimental evidence. Environ Res. 1982 Oct;29(1):238–244. [PubMed]
  • Davis JM, Bolton RE, Miller BG, Niven K. Mesothelioma dose response following intraperitoneal injection of mineral fibres. Int J Exp Pathol. 1991 Jun;72(3):263–274. [PMC free article] [PubMed]
  • Wagner JC, Skidmore JW, Hill RJ, Griffiths DM. Erionite exposure and mesotheliomas in rats. Br J Cancer. 1985 May;51(5):727–730. [PMC free article] [PubMed]
  • Baris YI. Fibrous zeolite (erionite)-related diseases in Turkey. Am J Ind Med. 1991;19(3):374–378. [PubMed]
  • Fraire AE, Greenberg SD, Spjut HJ, Dodson RF, Williams G, Lach-Pasko E, Roggli VL. Effect of erionite on the pleural mesothelium of the Fischer 344 rat. Chest. 1997 May;111(5):1375–1380. [PubMed]
  • Baris YI, Sahin AA, Ozesmi M, Kerse I, Ozen E, Kolacan B, Altinörs M, Göktepeli A. An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgüp in Anatolia. Thorax. 1978 Apr;33(2):181–192. [PMC free article] [PubMed]
  • Bariş B, Demir AU, Shehu V, Karakoca Y, Kisacik G, Bariş YI. Environmental fibrous zeolite (erionite) exposure and malignant tumors other than mesothelioma. J Environ Pathol Toxicol Oncol. 1996;15(2-4):183–189. [PubMed]
  • Metintas M, Hillerdal G, Metintas S. Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort. Eur Respir J. 1999 Mar;13(3):523–526. [PubMed]
  • Baris YI, Artvinli M, Sahin AA, Sebastien P, Gaudichet A. Diffuse lung fibrosis due to fibrous zeolite (erionite) exposure. Eur J Respir Dis. 1987 Feb;70(2):122–125. [PubMed]
  • Sebastien P, Gaudichet A, Bignon J, Baris YI. Zeolite bodies in human lungs from Turkey. Lab Invest. 1981 May;44(5):420–425. [PubMed]
  • Sébastien P, Awad L, Bignon J, Petit G, Barris YI. Ferruginous bodies in sputum as an indication of exposure to airborne mineral fibers in the mesothelioma villages of Cappadocia. Arch Environ Health. 1984 Jan-Feb;39(1):18–23. [PubMed]
  • Gylseth B, Churg A, Davis JM, Johnson N, Morgan A, Mowe G, Rogers A, Roggli V. Analysis of asbestos fibers and asbestos bodies in tissue samples from human lung. An international interlaboratory trial. Scand J Work Environ Health. 1985 Apr;11(2):107–110. [PubMed]
  • Dumortier P, Coplü L, de Maertelaer V, Emri S, Baris I, De Vuyst P. Assessment of environmental asbestos exposure in Turkey by bronchoalveolar lavage. Am J Respir Crit Care Med. 1998 Dec;158(6):1815–1824. [PubMed]
  • De Vuyst P, Dumortier P, Moulin E, Yourassowsky N, Yernault JC. Diagnostic value of asbestos bodies in bronchoalveolar lavage fluid. Am Rev Respir Dis. 1987 Nov;136(5):1219–1224. [PubMed]
  • Dumortier P, De Vuyst P. Object-marking, a bridge between light and analytical electron microscopy for particles characterization. J Electron Microsc Tech. 1988 Feb;8(2):229–230. [PubMed]
  • De Vuyst P, Karjalainen A, Dumortier P, Pairon JC, Monsó E, Brochard P, Teschler H, Tossavainen A, Gibbs A. Guidelines for mineral fibre analyses in biological samples: report of the ERS Working Group. European Respiratory Society. Eur Respir J. 1998 Jun;11(6):1416–1426. [PubMed]
  • De Vuyst P, Mairesse M, Gaudichet A, Dumortier P, Jedwab J, Yernault JC. Mineralogical analysis of bronchoalveolar lavage fluid as an aid to diagnosis of "imported" pleural asbestosis. Thorax. 1983 Aug;38(8):628–629. [PMC free article] [PubMed]
  • De Vuyst P, Dumortier P, Gevenois PA. Analysis of asbestos bodies in BAL from subjects with particular exposures. Am J Ind Med. 1997 Jun;31(6):699–704. [PubMed]
  • Teschler H, Thompson AB, Dollenkamp R, Konietzko N, Costabel U. Relevance of asbestos bodies in sputum. Eur Respir J. 1996 Apr;9(4):680–686. [PubMed]
  • Churg AM, Warnock ML. Asbestos and other ferruginous bodies: their formation and clinical significance. Am J Pathol. 1981 Mar;102(3):447–456. [PMC free article] [PubMed]
  • Morgan A, Holmes A. The enigmatic asbestos body: its formation and significance in asbestos-related disease. Environ Res. 1985 Dec;38(2):283–292. [PubMed]
  • Morgan A, Holmes A. Concentrations and dimensions of coated and uncoated asbestos fibres in the human lung. Br J Ind Med. 1980 Feb;37(1):25–32. [PMC free article] [PubMed]
  • Brown RC, Davies R, Rood AP. Modification of fibrous Oregon erionite and its effects on in vitro activity. IARC Sci Publ. 1989;(90):74–80. [PubMed]
  • Kelsey KT, Yano E, Liber HL, Little JB. The in vitro genetic effects of fibrous erionite and crocidolite asbestos. Br J Cancer. 1986 Jul;54(1):107–114. [PMC free article] [PubMed]

Articles from Occupational and Environmental Medicine are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...